StreetInsider.com News Articles

Form 424B3 EUDA Health Holdings

Tue, 11 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260811/26902143.html

Form 424B3 EUDA Health Holdings

Tue, 11 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260811/26902143.html

Form EFFECT EUDA Health Holdings

Tue, 11 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26900704.html

Form EFFECT EUDA Health Holdings

Tue, 11 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26900704.html

Form F-3/A EUDA Health Holdings

Fri, 31 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260731/26851202.html

Form F-3/A EUDA Health Holdings

Fri, 31 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260731/26851202.html

Form 6-K EUDA Health Holdings For: Jul 31

Fri, 31 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26846989.html

Form 6-K EUDA Health Holdings For: Jul 31

Fri, 31 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26846989.html

EUDA Health details MOU for iPSC cell therapy collaboration

Thu, 30 Jul 2026 06:01:29 -0400

EUDA Health Holdings Limited (NASDAQ: EUDA) has provided additional details on a non-binding Memorandum of Understanding signed July 15, 2026, with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. for a collaborative cell therapy program targeting oncology and wellness applications.

Under the MOU, the Singapore-based company plans to fund the joint collaboration and facilitate commercialization, while GO POSB would contribute its induced pluripotent stem cell platform and a clinical-grade universal tumor organoid bank. Shenzhen Innovation Immunotechnology would provide Natural Killer cell engineering capabilities, GMP-compliant manufacturing, and pre-release testing at its Shenzhen facility.

The parties intend to develop off-the-shelf cell

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

Thu, 30 Jul 2026 06:00:00 -0400

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”).

Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

Thu, 30 Jul 2026 06:00:00 -0400

Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

Thu, 30 Jul 2026 06:00:00 -0400

Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products

Thu, 30 Jul 2026 06:00:00 -0400

Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem

Form 6-K EUDA Health Holdings For: Jul 28

Tue, 28 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260728/26827618.html

Form 6-K EUDA Health Holdings For: Jul 28

Tue, 28 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260728/26827618.html

EUDA Health signs MOU for iPSC cell therapy collaboration

Tue, 28 Jul 2026 06:01:27 -0400

EUDA Health Holdings Limited (NASDAQ: EUDA), a Singapore-based distributor of wellness and non-invasive healthcare products, announced it has signed a Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation cell therapies derived from induced pluripotent stem cells.

According to the press release, the MOU outlines the three parties' intentions to collaborate on the development, manufacturing, and commercialization of off-the-shelf oncology cell therapies intended for cancer treatment and wellness applications.

Alfred Lim, Chief Executive Officer of EUDA, stated: "This collaborative agreement represents a significant milestone for our company. The agreement aligns with our

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

Tue, 28 Jul 2026 06:00:00 -0400

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”).

The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

Tue, 28 Jul 2026 06:00:00 -0400

The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

Tue, 28 Jul 2026 06:00:00 -0400

The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization

EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies

Tue, 28 Jul 2026 06:00:00 -0400

The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization

Form 424B5 EUDA Health Holdings

Wed, 22 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798050.html

Form 424B5 EUDA Health Holdings

Wed, 22 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260722/26798050.html

Form F-3/A EUDA Health Holdings

Fri, 17 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260717/26784910.html

Form F-3/A EUDA Health Holdings

Fri, 17 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260717/26784910.html

Form F-3/A EUDA Health Holdings

Tue, 07 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260707/26741985.html